Reducing the limitations of cisplatin, such as neurotoxicity, ototoxicity and nephrotoxicity, is becoming more vital because of the around 90% success rate of cisplatin in cancer treatment . The other limitation is drug resistance against cisplatin in cancer treatment . For example, the loss of signal-regulated kinase (ERK) in ovarian carcinoma cells results in resistance against cisplatin . The origin of resistance against the drug can mainly be rooted in HSA (human serum albumins), influx and efflux transporter (accumulation of the drug into a cancerous cell), DNA repair mechanism (base excision repair, nucleotide repair, mismatch repair), and raised the level of glutathione . Fortunately, novel approaches, such as supramolecular coordination complexes (SCCs) , can solve cisplatin limitations, including neurotoxicity, ototoxicity and nephrotoxicity, by accomplishing drug resistance . SCCs, such as metallacages, can be easily synthesized and modified in various geometries and redox states, allowing their features to be altered. This flexibility helps overcome the limitations of cisplatin . SCCs are highly versatile and can form various architectures, making them promising candidates for applications such as drug delivery . In particular, SCCs have shown potential for encapsulating cisplatin, a widely used chemotherapy drug, due to their ability to create well-defined, protective cavities that enhance the drug's stability and targeted delivery . They offer several advantages: voids for applications such as drug delivery, significant electrical conductivity and high charge mobility, very low density, complex unit cells, considerable van der Waals interactions, readily attainable porosity, and thermal stability .